Drugs / Cetrelimab
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07027514 | Oct 2025 → Jun 2027 expected | non-small cell lung carcinoma | Ankyra Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT06311578 | Apr 2024 → Nov 2028 expected | neoplasm | Johnson & Johnson Enterprise Innovation Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05818683 | Apr 2023 → Aug 2027 expected | prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05242445 | Apr 2022 → May 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03547037 | Aug 2018 → Jul 2022 | neoplasm | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT03551782 | Jun 2018 → Nov 2021 | castration-resistant prostate carcinoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05908734 | May 2023 → Jan 2027 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03473743 | Apr 2018 → Sep 2022 overdue | urothelial carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02908906 | Nov 2016 → Nov 2023 overdue | neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06511648 | Mar 2023 → Jul 2026 overdue | infiltrating bladder urothelial carcinoma | Spanish Oncology Genito-Urinary Group | Recruiting | No outcome recorded |
| Phase 2 | NCT04919512 | Jul 2022 → Feb 2025 | urinary bladder neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04926181 | Mar 2022 → Mar 2024 | prostate cancer, small cell carcinoma | Rahul Aggarwal | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04592237 | Dec 2020 → Dec 2027 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate small cell carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04640623 | Dec 2020 → Jul 2025 overdue | urinary bladder neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03431350 | Mar 2018 → Aug 2021 overdue | castration-resistant prostate carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03357952 | Nov 2017 → Oct 2018 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05714202 | Mar 2023 → Sep 2029 expected | urinary bladder cancer | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04658862 | Dec 2020 → Dec 2026 expected | urinary bladder neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT07525141 Background | May 2026 → Jan 2028 expected | neoplasm | Johnson & Johnson Enterprise Innovation Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06116786 Background | Nov 2023 → Apr 2027 expected | non-small cell lung carcinoma | Johnson & Johnson Enterprise Innovation Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06534190 Background | Mar 2025 → Nov 2028 expected | — | University Medical Center Groningen | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
All press releases naming this drug 10 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cetrelimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05714202 ↗ |
| Known as | CET | “Cetrelimab (CET) combination” NCT06511648 ↗ |
| Known as | JNJ-63723283 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03547037 ↗ |
| Action | Inhibit | “monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283)” PMID 42313189 ↗ Jun 20261“Programmed cell death protein 1 inhibitor” CHEMBL4298001 ↗ |
| Modality | Monoclonal antibody | “JNJ-63723283, an Anti-PD-1 Monoclonal Antibody” NCT02908906 ↗ |
| Route | Intravenous | “JNJ-63723283 will be administered by IV infusion or SC injection or infusion.” NCT02908906 ↗ |
| Route | Subcutaneous | “JNJ-63723283 will be administered by IV infusion or SC injection or infusion.” NCT02908906 ↗ |
| Target | PDCD1 | “Programmed cell death protein 1 inhibitor” CHEMBL4298001 ↗ |